Unlocking Brain-Specific Alzheimer’s Biomarkers: The Power of BDpTau217 and BDpTau181 Assays for Research

As the landscape of Alzheimer’s disease (AD) research continues to evolve, there is increasing demand for blood-based biomarkers that offer both precision and scalability. Among these, brain-derived phosphorylated tau (BDpTau) markers are gaining momentum for their unique ability to measure tau proteins sourced exclusively from the brain. These biomarkers address a critical limitation of conventional pTau assays, which may reflect peripheral tau not specific to AD pathology.

At Eve Technologies, we now offer BDpTau217 and BDpTau181 assays for research use only (RUO), optimized on the Meso Scale Discovery® (MSD®) electrochemiluminescence platform. These services are designed for Alzheimer’s researchers, diagnostics developers, and pharma teams seeking ultrasensitive tau quantification in human plasma, serum, or CSF. With our flexible pay-per-well model, it’s never been easier to incorporate cutting-edge biomarkers into your research pipeline.

What Is BDpTau and Why Does It Matter?

BDpTau assays overcome this limitation by:

• Measuring only brain-derived tau species, increasing specificity
• Delivering cleaner and more reliable signals in blood and CSF
• Showing stronger correlations with amyloid and tau PET imaging

Several high-impact studies have confirmed that BD-tau biomarkers outperform total tau and standard pTau assays in distinguishing Alzheimer’s from other neurodegenerative conditions and in identifying early-stage pathology. For researchers developing blood-based Alzheimer’s biomarkers, BDpTau enables more accurate quantification, better diagnostic confidence, and improved monitoring of disease progression.

Advantages Over Traditional pTau Assays

BDpTau assays offer several key advantages compared to traditional blood-based pTau tests:

• Brain Specificity: The capture antibody in BD-pTau assays binds only CNS tau isoforms (1). This drastically reduces signals from peripheral tau and increases specificity to AD brain pathology. Traditional assays (even high-sensitivity platforms) measure pTau from all sources.
• Alzheimer’s Disease Specificity: BD-pTau measures correlate strongly with Alzheimer’s biomarkers and pathology. This specificity can differentiate AD from other neurodegenerative diseases and improve diagnostic accuracy.
• Higher Fold-Change: Research suggests BD-pTau217 yields a larger dynamic range in patient samples. A clinical evaluation found BD-pTau217 had a higher fold-increase between AD and control samples than conventional plasma pTau217, with fewer borderline results(2). This can help avoid equivocal results and strengthen statistical power in studies.
• Ultrasensitive Detection: BDpTau assays, particularly those run on high-sensitivity platforms such as MSD®, achieve femtogram-level detection, enabling precise measurement of low-abundance tau species in plasma and serum.
• Improved Early Detection: By isolating tau proteins that originate exclusively from the brain, BDpTau reduces background “noise,” making it more effective for identifying early or preclinical Alzheimer’s pathology.

BDpTau217: The Next Step in Biomarker Evolution

Among all phosphorylated tau biomarkers studied in Alzheimer’s research, pTau217 has emerged as one of the most reliable and disease-specific indicators of Alzheimer’s pathology. It consistently outperforms pTau181 in distinguishing Alzheimer’s disease (AD) from other neurodegenerative conditions, and shows stronger correlation with both amyloid-β and tau PET imaging findings.

But the real breakthrough comes with the development of the BDpTau217 assay — a brain-derived version of pTau217 that captures only tau proteins originating from the central nervous system. This advanced format removes the confounding influence of peripheral tau, making the signal cleaner, more specific, and more predictive of true Alzheimer’s-type neurodegeneration.

Why BDpTau217 Matters for Alzheimer’s Blood Biomarker Research

• Higher diagnostic specificity: BDpTau217 eliminates background noise by filtering out tau from non-brain tissues
• Improved fold-change: Studies suggest BDpTau217 shows a greater difference in concentration between Alzheimer’s patients and cognitively normal individuals, improving research sensitivity
• Early detection power: BDpTau217 levels rise earlier in the disease course than many traditional biomarkers, making it ideal for identifying preclinical AD or tracking early-stage tauopathy

Now we offer Human MSD® Discovery Assay® Brain Derived-pTau217 (MSDBDT217) on the MSD® S-PLEX® platform, which enables femtogram-level detection of this key biomarker in human serum, plasma, or CSF samples.

What About BDpTau181?

While BDpTau217 is gaining recognition as a leading-edge biomarker for Alzheimer’s disease, BDpTau181 also holds significant value in Alzheimer’s research — especially for teams seeking continuity with legacy biomarker studies or multi-marker validation strategies.

BDpTau181 is the brain-derived form of phosphorylated tau at threonine 181. It shares the same core advantage as BDpTau217: it detects tau proteins exclusively from the central nervous system, excluding peripheral sources that can dilute signal clarity in traditional blood assays.

Key Reasons to Use BDpTau181 in Alzheimer’s Research:

• Legacy comparability – Many published studies and clinical trials have used pTau181 as a baseline tau biomarker. BDpTau181 offers enhanced specificity while still aligning with prior datasets.
• Complementary tau dynamics – Tau phosphorylation sites (e.g. 181 vs. 217) may reflect different aspects or time points in AD pathology. Using BDpTau181 alongside BDpTau217 allows researchers to profile tau changes across disease progression.

BDpTau217 and BDpTau181 at Eve Technologies

At Eve Technologies, BDpTau217 and BDpTau181 assays are offered on a pay-per-well basis using the MSD® S-PLEX® platform, designed for researchers who need high-sensitivity biomarker measurements without investing in full assay setup or plate purchases.

Whether used as a standalone marker or in tandem with BDpTau217, BDpTau181 gives research teams another powerful, brain-targeted tool for exploring tau pathology in Alzheimer’s disease.

Please note: These assays are intended for research use only (RUO) and are not approved for diagnostic or clinical decision-making.

References

1. Gonzalez-Ortiz F et al. Brain-derived tau (BD-tau) is a blood biomarker specific to AD-type neurodegeneration. Brain, 146(3), 1152–1165. https://doi.org/10.1093/brain/awac407
2. Clinical Laboratory Products (CLP) Magazine. (2023). New Blood-Based Assay Targets Brain-Specific Alzheimer’s Biomarker. https://clpmag.com/disease-states/dementias-alzheimer/new-blood-based-assay-targets-brain-specific-alzheimers-biomarker/
3. Gonzalez-Ortiz, F., Kirsebom, BE., Contador, J. et al. Plasma brain-derived tau is an amyloid-associated neurodegeneration biomarker in Alzheimer’s disease. Nat Commun 15, 2908 (2024). https://doi.org/10.1038/s41467-024-47286-5